Stoke Therapeutics Files 8-K on Officer/Director Changes
Ticker: STOK · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $715,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, filing
Related Tickers: STOK
TL;DR
Stoke Therapeutics (STOK) filed an 8-K, reporting leadership changes and financial docs. Keep an eye on this.
AI Summary
Stoke Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported as October 5, 2025. The company is incorporated in Delaware and headquartered in Bedford, Massachusetts.
Why It Matters
This filing indicates potential shifts in leadership or governance at Stoke Therapeutics, which could impact the company's strategic direction and operational management.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- October 5, 2025 (date) — Earliest event reported
- October 6, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Bedford, Massachusetts (location) — Principal Executive Offices
FAQ
What specific officer or director positions were affected by the changes reported in the 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided excerpt.
Are there any new compensatory arrangements for officers detailed in this filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specifics of these arrangements are not included in the provided text.
What financial statements or exhibits are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the content of these documents is not specified in the excerpt.
What is the significance of the 'Former Company' information listed?
The filing notes 'ASOthera Pharmaceuticals, Inc.' as the former company name, with a date of name change in 2014, indicating a historical corporate identity.
What is the SIC code for Stoke Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Stoke Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,606 words · 6 min read · ~5 pages · Grade level 12.5 · Accepted 2025-10-06 07:30:15
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
- $715,000 — s: (i) an initial annual base salary of $715,000 per year (the "Initial Base Salary"), (
- $500,000 — onus for 2025, (iii) a sign-on bonus of $500,000, which is repayable if Mr. Smith resign
Filing Documents
- d55930d8k.htm (8-K) — 34KB
- d55930dex101.htm (EX-10.1) — 55KB
- d55930dex102.htm (EX-10.2) — 28KB
- 0001193125-25-230925.txt ( ) — 254KB
- stok-20251005.xsd (EX-101.SCH) — 3KB
- stok-20251005_lab.xml (EX-101.LAB) — 17KB
- stok-20251005_pre.xml (EX-101.PRE) — 11KB
- d55930d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Executive Employment Agreement, by and between the Company and Ian F. Smith, effective as of October 6, 2025 10.2 Change of Control and Severance Agreement, by and between the Company and Ian F. Smith, effective as of October 6, 2025 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STOKE THERAPEUTICS, INC. Date: October 6, 2025 By: /s/ Thomas E. Leggett Thomas E. Leggett Chief Financial Officer